Imatinib Mesylate
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If containing pyridine ring structure
Pyridine and derivatives are specifically classified under 2933.59, taking precedence over the general 'other' category.
If imported as finished dosage form like tablets
Finished pharmaceutical products containing this active ingredient fall under Chapter 30 as medicaments.
If caffeine or its salts
Specific provision for caffeine exists earlier in the heading, but this drug doesn't qualify.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Obtain FDA approval and Drug Master File (DMF) prior to import as it's a pharmaceutical substance
• Ensure Certificate of Analysis (CoA) verifies purity >99% and compliance with USP standards
• Avoid misclassification as a research chemical; declare as bulk drug substance for medicinal use
Related Products under HTS 2933.99.75.00
Erlotinib Hydrochloride
Erlotinib hydrochloride is an epidermal growth factor receptor (EGFR) inhibitor used in non-small cell lung cancer treatment. As a quinazoline derivative (aromatic heterocycle with nitrogen), it qualifies under HTS 2933.99.75.00 for aromatic heterocyclic drugs.
Nilotinib Hydrochloride
Nilotinib hydrochloride treats imatinib-resistant chronic myelogenous leukemia. As a pyrimidine derivative with aromatic nitrogen heterocycles, it falls under the 'drugs: other' provision of HTS 2933.99.75.00.
Gefitinib
Gefitinib is an EGFR tyrosine kinase inhibitor for lung cancer treatment. This 4-anilinoquinazoline (aromatic N-heterocycle) is classified as a bulk pharmaceutical drug under HTS 2933.99.75.00.
Osimertinib Mesylate
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Brigatinib
Brigatinib is an ALK inhibitor for lung cancer treatment. This macrocyclic aromatic nitrogen-heterocycle drug substance imports under HTS 2933.99.75.00.
Alectinib Hydrochloride
Alectinib hydrochloride targets ALK fusion proteins in lung cancer. As an isoquinoline derivative (aromatic N-heterocycle), classified under HTS 2933.99.75.00 for drugs.